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Characterization of Risk From Airborne Benzene Exposure in the State of Florida
Giffe Johnson
ABSTRACT
Environmental airborne benzene is a ubiquitous hazardous air pollutant whose
emissions are generated from multiple sources, including industrial emissions, fuel
station emissions, and automobile emissions. Chronic occupational exposures to
elevated levels of benzene are known to be associated with leukemic cancers, in
particular, acute myeloid leukemia (AML), though epidemiological evidence
regarding environmental exposures and subsequent AML developmentis lacking.
This investigation uses historical airborne monitoring data from six counties in the
State of Florida to characterize the environmental cancer risk from airborne benzene
concentrations using current Federal and State regulatory analysis methodology, and
a comparative analysis based on occupational epidemiological evidence. Airborne
benzene concentrations were collected from 24 air toxics monitoring stations in
Broward, Duval, Orange, Miami-Dade, Hillsborough, and Pinellas counties. From
the years 2003 – 2006, 3,794 air samples were collected using 8, 12, and 24 hr
samples with sub-ambient pressure canister collectors consistent with EPA benzene
methodological protocols 101 and 176. Mean benzene concentrations, by site, ranged
from 0.18 – 3.58 ppb. Using risk analysis methodology consistent with the EPA and
the Florida Department of Environmental Protection (FLDEP) the resulting cancer
risk estimates ranged from 4.37 x 10-6 to 8.56 x 10-5, exceeding the FLDEP’s
x

acceptable cancer risk level, 1 x 10-6 for all monitoring sites. The cumulative lifetime
exposures were calculated in ppm-years by site, ranging from 0.036 – 0.702 ppmyears. A comparative analysis with available epidemiological literature revealed that
associations between benzene exposure and cancer outcomes were related to
cumulative lifetime exposures in great excess of 1 ppm-years. The results of this
investigation indicate that it is not reasonable to expect additional cancer outcomes in
Florida residents as a result of airborne benzene exposures consistent with measured
concentrations, despite the fact that all regulatory risk calculations exceed acceptable
cancer risk levels in the State of Florida.

xi

Chapter 1.0: Introduction
1.1 Overview of Benzene Related Health Research
Concern over the health hazards of benzene exposure has existed since the early 20th
century. Researchers began reporting acute toxicities from extremely high exposures
(3,000 to 20,000 ppm) such as anesthesia, confusion, and death in the 1920’s (1-3).
Chronic toxicities began to be reported soon after, with hematologic toxicity being
most noted in the suppression of red and white blood cells, exhibiting as pancytopenia
and aplastic anemia (1-6). One of the first cases of leukemia reported to be associated
with benzene exposure occurred in 1928, though the link between benzene exposure
and leukemia was not firmly established until several decades later (7). The
carcinogenic nature of benzene began to come into focus in the 1970s, when larger
groups of exposed workers started to see inordinate numbers of leukemia cases (813). Goguel et al. 1967, Girard and Revol 1970, and Aksoy et al. 1972 reviewed
several of the first case series that seemed to indicate a more specific relationship
between excessive benzene exposures and acute myelogenous leukemia (AML) (1416). Vigliani et al. 1964 and Askoy et al. 1974 made the first attempts to characterize
the risk of benzene exposure and leukemia, but unfortunately lacked a sufficient
exposure assessment to produce any reliable estimates (17-18). In the 1980s and
1990s, the attention focused on exposure to petroleum and chemical workers to more
clearly assess specific levels of benzene exposure and the risk of leukemogenesis (7).
As well, non-occupational exposures began to be explored in this time period,
1

focusing on indoor air, tobacco usage, and self-service gasoline station benzene
exposures (19-20). The focus of research in the 21st century undoubtedly lies in the
pursuit of establishing a clear dose-response relationship between low level benzene
exposures and leukemogenesis, in both occupational and environmental settings, in
order to ascertain a level benzene exposure that will ensure the safety of workers, as
well as the safety of the general population.

1.2.1 Acute Lethality
The inhalation LC50 value for rats has been determined to lie between 13,700 ppm
and 16,000 ppm for a 4-hour exposure (21-22). Green et al. 1981 observed mice
exposed by inhalation to doses of benzene up to 4,862 ppm, 6 hours/day for 5 days
without lethality (23). Deaths in humans from acute benzene exposures are often
poorly characterized, but it has been estimated that 5 to 10 minutes of exposure to
20,000 ppm is most likely fatal (24). The pathology in cases of lethal benzene
exposures may be described by asphyxiation, respiratory arrest, central nervous
system depression, suspected cardiac collapse, cyanosis, hemolysis, and congestion or
hemorrhage of organs (25-28).

1.2.2 Respiratory Toxicity
Several adverse respiratory effects have been reported in humans after acute
exposures to benzene vapors between 30 and 300 ppm for a period of several days or
weeks in relatively higher exposures, or as long as a year for relatively lower
exposures. These effects include mucous membrane irritation, dyspnea, nasal
2

irritation, and sore throat (25-30). In extremely high exposures that resulted in
fatalities, pulmonary edema, acute granular tracheitis, laryngitis, bronchitis, and
massive hemorrhaging have been observed (25-27).

1.2.3 Dermal Toxicity
Skin irritation has been noted at airborne occupational exposures of >60 ppm for up
to 3 weeks as well as with extremely high acute exposures (25, 29).

1.2.4 Neurological Toxcity
At acute exposure levels between 300 and 3,000 ppm, neurological effects have been
observed such as drowsiness, dizziness, headache, vertigo, tremor, delirium, and loss
of consciousness (29, 31-33). There is some evidence of neurological toxicity from
excessive chronic exposures (~200 ppm) in the form of global atrophy of lower
extremities and distal neuropathy of upper extremities, though this is based on a
limited number of cases and a crude estimation of exposure (34).

1.2.5 Reproductive Toxicity
There has been some suggestion that benzene exposure may lead to dysmenorrheal,
disturbances in the menstrual cycle, and spontaneous abortion. Unfortunately, the
research related to these possible effects does not have accurate exposure
measurements and is plagued by confounding factors such as mixed chemical
exposures (35-37).
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1.2.6 Hematological Toxicity
Hematological effects from acute exposures have not been well established, but there
is some evidence that indicates leukopenia, anemia, and thrombocytopenia may occur
after more than 2 days of occupational exposure to more than 60 ppm benzene in a
small portion of workers (29). Chronic exposures to benzene in excess of
occupational regulatory levels (~ 10 ppm) for many years may result in pancytopenia,
the reduction in the number of all three major types of blood cells: erythrocytes (red
blood cells), thrombocytes (platelets), and leukocytes (white blood cells).
Additionally, aplastic anemia may result, a more severe condition wherein the bone
marrow ceases to function and the stem cells never reach maturity. Some research
indicates that aplastic anemia may be a precursor to myelogenous leukemia (38-49).

There are several studies clearly indicating that high level chronic exposure is
associated with hematological abnormalities. Askoy et al. 1971, 1972 found various
increases in hematological abnormalities (leukopenia, thrombocytopenia,
eosinophilia, pancytopenia, and hypoplastic, acellular, hyperplastic, or normoblastic
bone marrow) with exposures estimated to be between 15 to >200 ppm (50-51).
Dosemeci et al. 1996 found similar abnormalities when assessing rubber
manufacturing workers with more accurately defined exposure estimates ranging
from 5 to >40 ppm (52). At lower levels of chronic exposure (0.01 – 1.4 ppm),
evidence indicates chronic benzene exposure does not produce hematological toxicity
(53-55).

4

1.3 Benzene as a Carcinogen
As previously mentioned, benzene has been a suspected leukemogen, particularly the
myeloid cell type, since the late 1920’s, though the causal association between
benzene and leukemia had not been confirmed until the 1970’s. The carcinogenic
nature of benzene, in terms of the specific mechanism of action has not been clearly
established. An examination of benzene metabolism does provide some insight,
however, for potential mechanisms by which the metabolites of benzene may function
as carcinogens.

1.3.1 Benzene Metabolism
The metabolism of benzene in humans has been established primarily from studies
using inhalation exposures. Benzene is excreted both unchanged through the lungs
and as metabolites (as well as some unmetabolized benzene) in the urine. Metabolites
are produced in the liver and carried to the bone marrow (though additional
metabolism may occur in the marrow itself) where the greatest potential for benzene
related toxicity exists. As illustrated in Figure 1, benzene metabolism is driven by
cytochrome P-450 2E1 (CYP2E1) catalyzed oxidation to form benzene oxide (56-57).
Several pathways are involved in the metabolism of benzene oxide, the predominant
pathway being the nonenzymatic rearrangement to form phenol, the initial product of
benzene metabolism of major importance regarding benzene toxicity (58-59).
CYP2E1 also catalyzes the oxidation of phenol to catechol or hydroquinone, which
are oxidized via myeloperoxidase (MPO) to the reactive metabolites 1,2- and 1,4benzoquinone, respectively and the reverse reaction (reduction of 1,2- and 1,45

benzoquinone to catechol and hydroquinone, respectively) is catalyzed by NAD(P)H
quinone oxidoreductase (NQ01). Both catechol and hydroquinone may be converted
to the reactive metabolite 1,2,4-benzenetriol, again, by CYP2E1 catalysis. 1,2,4benzenetriol is potentially the most toxic metabolite as a result of having a third
reactive hydroxyl group (60).

However, as a minor pathway, benzene oxide may also undergo epoxide hydrolasecatalyzed conversion to benzene dihydrodiol and subsequent dihydrodiol
dehydrogenase-catalyzed conversion to catechol (60-62). Each of the phenolic
metabolites of benzene (phenol, catechol, hydroquinone, and 1,2,4-benzenetriol) can
undergo sulfonic or glucuronic conjugation, the conjugates of phenol and
hydroquinone being the major urinary metabolites of benzene (60, 63-65). Other
minor metabolic pathways for benzene oxide that produce potentially less toxic
metabolites include the reaction with glutathione (GSH) to form S-phenylmercapturic
acid, and the iron catalyzed ring-opening conversion to trans,trans-muconic acid,
possibly through the reactive trans,transmuconaldehyde intermediate (60, 66-75).

6

Figure 1: Benzene metabolic pathways.

From the ATSDR Toxicological Profile on Benzene; originally adapted from Nebert et al. 2002 and
Ross 2000 (11, 60, 67).
ADH = alcohol dehydrogenase; ALDH = aldehyde dehydrogenase; CYP2E1 = cytochrome P-450 2E1;
DHDD = dihydrodiol dehydrogenase; EH = epoxide hydrolase; GSH = glutathione; MPO =
myeloperoxidase; NQ01 = NAD(P)H:quinone oxidoreductase

1.3.2 Mechanism of Action
Several animal studies have found compelling evidence that the genotoxicity
exhibited in mice after benzene exposure is directly attributed to the metabolites of
benzene rather than benzene itself. Valentine et al. 1996a, 1996b used transgenic
knockout mice for the hepatic CYP2E1 gene, which prevents these mice from
metabolizing benzene in the liver. After both transgenic mice and wild-type mice
7

were exposed to 200 ppm of benzene for 6 hours a day for 5 days, the genotoxicity
observed in the wild-type mice was notably absent in the transgenic mice (76-77).
Similar results have been found in other studies where Cytochrome P-450 enzyme
inhibitors were used on wild type mice to inhibit benzene metabolism, which
effectively attenuated benzene induced genotoxicity (78-81).

Several investigations suggest that the covalent binding of benzene metabolites to
cellular macromolecules is related to benzene's mechanism of toxicity, specifically
the formation of adducts with nucleic acids, but also with various proteins (82-90).
The reactive metabolites that exhibit these binding properties and have been proposed
as agents of benzene hematotoxic and leukemogenic effects include benzene oxide,
reactive products of the phenol pathway (catechol, hydroquinone, 1,2,4-benzenetriol,
and 1,4-benzoquinone). Smith 1996a, 1996b noted that the phenolic metabolites can
also be metabolized by bone marrow peroxidases, such as myeloperoxidase, to highly
reactive semiquinone radicals and quinones that stimulate the production of reactive
oxygen species (91-92). All of these reactive metabolites are capable of damaging
nuclear proteins and enzymes such as tubulin, histone proteins, topoisomerase II,
other DNA associated proteins, as well as DNA itself in the form of strand breakage,
mitotic recombination, chromosome translocations, and aneuploidy. Damage to stem
or early progenitor cells could potentially be expressed as hematopoietic and
leukemogenic effects (82-97).
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As benzene toxicity is thought to be driven by metabolism, it is important to note that
the available data collected on metabolic pathways is primarily garnered from animal
studies. This being the case, it is imperative to examine interspecies differences in
the metabolism of benzene. Firstly, species differences exist in absorption and
retention of benzene. It has been observed that following 6-hour exposures to
concentrations of 7–10 ppm of benzene vapors, mice retain 20% of the inhaled
benzene, whereas rats and monkeys retain only 3–4% (98-99). Secondly, the rate of
metabolism differs among various species. Mice have a greater overall capacity to
metabolize benzene, compared to rats. It has been shown that an inhalation exposure
to 925 ppm results in an internal dose of 152 mg/kg in mice, only 15% of which was
excreted as unmetabolized benzene compared to an internal dose of 116 mg/kg in
rats, approximately 50% of which was excreted unchanged (98, 100). As it is
generally thought that humans more closely resemble mouse metabolic profiles
compared to rats, a more conservative metabolic rate is used to estimate human
metabolite production. As well, the more conservative absorption rate is used in the
development of the inhalation unit risk, with the assumption that humans absorb and
retain 50% of inhaled exposures (48).

1.4 Environmental Benzene Exposure
The USEPA Toxic Release Inventory (TRI) records indicates that 333,089 pounds of
benzene were released into the environment in the State of Florida in the year 2005
(101). Of these emissions, 115 pounds were recorded as releases into surface water,
and there was no amount of direct release into the soil reported. With the exception
9

of potential point source contamination of water and soil from accidental spillage that
results in extremely high levels of benzene in those media, environmental airborne
benzene represents the greatest potential for exposure to the general public.

Benzene is released into the atmosphere from both natural and industrial sources.
Natural sources include crude oil seeps, forest fires, and plant volatiles (102-103).
Major anthropogenic sources of benzene include automobile exhaust, automobile
refueling operations, and industrial emissions. It has been estimated that
environmental benzene emissions are highest in coke oven blast furnaces. However,
other sources that significantly contribute to emissions of benzene include
automobiles, petrochemical industries, waste water treatment plants, and petroleum
industries. Personal exposures include fueling passenger automobiles and cigarette
smoke. Cigarette smoke is the most important personal exposure in moderate to
heavy long-term smokers as it represents a persistent chronic exposure and can
contribute to indoor air pollution to the extent that indoor levels may become
significantly higher than ambient levels. Smokers are known to have measurably
higher levels of benzene in exhaled breath than non-smokers (104). The amount of
benzene measured in mainstream smoke ranges from 5.9 to 73 µg/cigarette. Larger
amounts of benzene have been found in side-stream smoke, ranging from 345 to 653
µg/cigarette (105). Vaporized benzene in the atmosphere may persist for a matter of
hours to approximately a week, depending on the concentration of hydroxyl
molecules present, which are the primary reactants involved in reducing airborne
benzene concentrations (106-107).
10

1.5 Research Objectives
It is evident that the majority environmental emissions of benzene are airborne, and
consequently, the greatest opportunity for exposure to the general public is through
the inhalation. It is also generally accepted that the health risk of greatest concern
from low level benzene exposures is cancer, specifically AML. As a result, the
primary objectives of this risk characterization deal directly with the cancer risks that
may potentially exist from ambient airborne concentrations of benzene.

Specifically, the objectives of the current research are as follows:
1. To characterize the ambient airborne benzene exposures in the State of Florida by
analyzing data from air sample measurements collected at air toxics monitoring sites
in the most populous counties from the years 2003 to 2006.
2. To characterize the cancer risk that may exist using the USEPA Risk Assessment
for Carcinogens methodology from the measured benzene concentrations in this
study.
3. To extrapolate the cumulative lifetime benzene exposure from the measured
benzene exposures in this study.
4. To perform a comparative analysis between epidemiological studies evaluating
cancer risk from cumulative lifetime benzene exposures to the cumulative lifetime
exposures as indicated by the measured benzene exposures in this study.
5. To draw conclusions as to the health risk presented by the ambient airborne
benzene exposures measured in this study.

11

The hypotheses to be tested in this research are the following:
1. A regulatory risk analysis based on measured benzene concentrations will result in
risk values in excess of the 1 x 10-6 acceptable risk level promulgated by the FLDEP;
2. Analysis of current epidemiological research will indicate that a threshold for
benzene induced leukemogenesis is evident, and;
3. Cumulative exposures extrapolated from measured airborne benzene
concentrations will be less than the evident threshold for benzene induced
leukemogenesis.

12

Chapter 2.0: Research Methods
2.1 Monitor Site Descriptions
In the State of Florida, six counties have active air toxics monitoring programs.
Within each county, there are varying numbers of monitors, in various locations in
terms of their proximity to benzene emission sources. Figures 2-7 represent the
locations of each monitor within each county, and their proximity to known benzene
emission sources, with the largest contributors of benzene emissions labeled. To
provide a sense of scale, and the potential influence of these emission sources on the
monitors, a two mile radius encircles the monitor sites. In Broward County (Figure 2)
the four active monitors fall primarily in Commercial and Residential areas, with all
monitors being located within two miles of known benzene emission sources. Duval
County (Figure 3) possesses more air toxic monitoring stations than any other county
in the State of Florida, and in addition to the Residential and Commercial monitor
categories, Duval County employs 23 monitors located near major highways and
roadways which may be heavily influenced by fugitive mobile benzene emissions.
Hillsborough County (Figure 4) has 3 active monitors in Commercial, Residential,
and Rural areas. Two monitors in Dade County (Figure 5) are located in Rural and
Commercial areas, respectively. Orange County (Figure 6) has a single active
monitoring station located in a Commercial area, with close proximity to major
roadways. Pinellas County (Figure 7) has 3 active monitor locations in Residential
areas, though it should be noted at least two of the monitors are within a two mile
13

proximity of known benzene emission sites, Site #2 located within two miles of the
largest benzene emission site for that county.
Figure 2: Benzene monitor locations and relevant benzene emission sources for
Broward County.

Benzene monitor locations within Broward County, Florida. Each site is encircled by
a 2 mile radius. Blue marks indicate known benzene emission sites; the highest
emission sources for this county are labeled (108).

14

Figure 3: Benzene monitor locations and relevant benzene emission sources for
Duval County.

Benzene monitor locations within Duval County, Florida. Each site is encircled by a
2 mile radius. Blue marks indicate known benzene emission sites; the highest
emission sources for this county are labeled (108).
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Figure 4: Benzene monitor locations and relevant benzene emission sources for
Hillsborough County.

Benzene monitor locations within Hillsborough County, Florida. Each site is
encircled by a 2 mile radius. Blue marks indicate known benzene emission sites; the
highest emission sources for this county are labeled (108).
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Figure 5: Benzene monitor locations and relevant benzene emission sources for
Dade County.

Benzene monitor locations within Dade County, Florida. Each site is encircled by a 2
mile radius. Blue marks indicate known benzene emission sites; the highest emission
sources for this county are labeled (108).
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Figure 6: Benzene monitor locations and relevant benzene emission sources for
Orange County.

Benzene monitor locations within Orange County, Florida. Each site is encircled by a
2 mile radius. Blue marks indicate known benzene emission sites; the highest
emission sources for this county are labeled (108).
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Figure 7: Benzene monitor locations and relevant benzene emission sources for
Pinellas County.

Benzene monitor locations within Pinellas County, Florida. Each site is encircled by
a 2 mile radius. Blue marks indicate known benzene emission sites; the highest
emission sources for this county are labeled (108).
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2.2 Data Collection
Six Florida Counties (Duval, Pinellas, Miami-Dade, Hillsborough, Orange, and
Broward) currently monitor and report air toxics levels to the United States
Environmental Protection Agency (USEPA). From the USEPA air toxics database,
all reported monitor levels were queried for Parameter 45201 Benzene in the State of
Florida for years 2003 – 2006 (108). The final dataset contained all reported airborne
benzene measurements from 23 individual monitoring sites during this time interval.

The sample collection method for Broward, Hillsborough, Miami-Dade, Orange, and
Pinellas counties uses the EPA method code 176 (109). This method uses 6 liter, subambient canisters for collection over either 12 or 24 hour periods. Chemical species
are quantified by Entech Proconcentrator Gas Chromatography/Mass Spectroscopy.
Duval County utilizes EPA method code 101 (109). This method utilizes subambient pressure canisters to collect samples over either 3, 4, 8, 12, or 24 hours (all
time periods were used for sampling beginning at various times throughout day or
night time hours). Chemical Species are quantified by Multi-Detector Gas
Chromatography. Both methods have the same calculated method detection limit
(MDL).

2.3 Assigning Values to Measurements Below the Method Detection Limit
In assessing low level environmental exposures, quantifying concentrations can be
limited by the physical capabilities of the equipment being used to measure the
airborne concentrations of a substance. When a measured value is below the method
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detection limit used in an exposure assessment, it is not considered a reliable value.
For these measurements, values are assigned based on assumptions made as to the
type of exposure being analyzed. For instance, as benzene is ubiquitous throughout
the atmosphere, it would not be a reasonable assumption that values under the MDL
would indicate a level of zero. Alternative methods have been proposed by Hornung
and Reed 1990 (128). The most conservative method of assigning values is to apply
the actual MDL to values that fall below the limit. This method will result in the
highest estimated mean exposure levels, and may significantly overestimate the actual
exposure in data for which there are many values below the MDL. Another proposed
methodology that is less conservative than using the actual MDL is to divide the
MDL by the square root of 2 (128). Hornung and Reed 1990 compared this method
with known censored datasets and found the comparison to maximum likelihood
estimates to be a highly accurate method of assigning values non-skewed data (128).
Hornung and Reed 1990 also found this methodology to be more appropriate than the
USEPA method of assigning values below the MDL as the MDL divided by 2 (128).
Dividing the MDL by 2 results in the least conservative estimation of mean values,
and might be criticized by some as resulting in an underestimation of mean exposure.
As a principle goal of the current research is to analyze the exposure data with
USEPA risk assessment methodology, it of great interest to calculate means that are
consistent with USEPA methods. However, in order to explore the effects of this data
treatment on estimated mean exposures, the alternative methods were also employed,
and the results were compared using the students t-test to assess if statistically
significant differences in estimated mean exposures have been produced as a result.
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Assigning values to measurements that are below the MDL may significantly affect
the calculated means if a large portion of the data set consists of values that fall below
the MDL. The standard procedure for assigning values below the MDL, as indicated
by the USEPA Guidelines for Carcinogen Risk Assessment, is to divide the MDL by
2 (110). This was the primary method used for calculating risk probabilities in the
current study. In order to assess the impact of values falling below the MDL on the
calculation of risk probabilities, two additional methods of assigning values to
measurements under the MDL are considered. The Upper Confidence Limit of the
Arithmetic Mean (UCL-AM) is also calculated by assigning values equal to the
MDL, and assigning values equal to the MDL divided by the square root of 2, when
recorded values are below the MDL. The students t-test has been used to determine
whether or not the different methodologies used in assigning values to measurements
under the MDL have a statistically significant impact on the calculation of UCLAMs.

2.4 USEPA Risk Analysis
A risk analysis of the data was performed using the USEPA Risk Assessment for
Superfund methodology (110). Risk estimates were produced for the probability of
developing cancer (AML) as a result of the measured benzene concentrations. The
exposure concentrations used in the calculation of risk and the risk probabilities were
derived using the USEPA software ProUCL version 4. The ProUCL program
calculates the 95% UCL-AM for normal, lognormal, gamma, and nonparametrically
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(non-normal) distributed concentrations of chemicals in air and recommends the most
appropriate UCL-AM for use depending on the distribution of the data. This analysis
was performed for the data retrieved for each individual site.

Risk probabilities were then calculated from all previously described UCL-AMs for
all sites. These risk probabilities were calculated by multiplying the UCL-AM by the
Inhalation Unit Risk (IUR) as prescribed in the USEPA Guidelines for carcinogen
risk assessment (110). The IUR used for benzene, 7.8 x 10-6, is consistent with both
the USEPA Integrated Risk Information System (IRIS) and the Florida Department of
Environmental Protection risk assessment methodology (49, 111).

2.5 Comparative Analysis
In order to conduct a comparative analysis between the benzene exposures found in
the current research and those found in epidemiological studies that have assessed the
relationship between cumulative lifetime benzene exposures (expressed as ppmyears) and cancer, monitored levels in the current data set have been extrapolated to
reflect cumulative lifetime exposures in ppm-years. This was performed using
USEPA methodology presented in the Region/ORD Workshop on Inhalation Risk
Assessment: A Superfund Focus (112). Using the UCL-AMs for calculating the risk
probability associated with each monitoring site, the cumulative exposure was
extrapolated into ppm-years with the following conversion factors: 20 m3/10 m3 x 7
days/5 days x 70 years/40 years = 4.9. This method of conversion accounts for both
the decreased inhalation rate associated with non-occupational airborne exposures as
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well as the increased exposure duration of 7 days a week for 70 years compared to
occupational exposures of 5 days a week over a 40 year working lifetime. The ORD
Workshop on Inhalation Risk Assessment indicates that the conversion factor
affecting the difference in inhalation rates adequately compensates for the difference
in daily exposure times (e.g. 24 hours of environmental exposure versus 8 hours of
occupational exposure) and that an additional conversion factor for this difference is
unnecessary (112).

A literature review using the PubMed/Medline database has been conducted to gather
all published, peer reviewed scientific literature regarding airborne benzene exposure
and cancer outcomes that contain comparisons of discreet ranges of lifetime exposure.
In comparing the cumulative lifetime benzene exposures derived from the current
research with cumulative benzene exposures from occupational cohorts, a weight of
evidence approach using the criteria for causal analysis has been made to determine if
there is potentially a threshold below which leukemogenesis does not occur. More
specifically, this comparative analysis determined if there is research to indicate there
is a potential association between levels of exposure measured in this dissertation
with leukemogenesis by assessing the levels of cumulative lifetime exposures found
in occupational cohorts that are associated with leukemogenesis.
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Chapter 3.0: Results
3.1 Descriptive Statistics
Tables 1 – 6 contain the summary statistics of the airborne benzene measurements
collected at each sampling site, by county. The number of samples, minimum
measured concentrations, maximum measured concentrations, mean concentrations,
median concentrations, and the standard deviation are reported for all sites for
samples collected between January 2003 and December 2006. As three different
methods were used to assign values to measurements below the MDL, summary
statistics were produced for each method for those sites that had measurements below
the MDL, and this is reflected in the following tables. For sites with no
measurements below the MDL, results from using any value assigning methodology
could not be reported.
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Table 1: Summary Statistics for airborne benzene samples collected between
January 2003 and December 2006 for all Broward County sampling sites. All
concentrations are µg/m3.
Site
1002

Site
2004

Site
3002

Site
5005

Number of Samples
Number Below MDL

218
13

181
21

186
6

224
29

MDLa
Minimum
Maximum
Mean
Median
SDd

0.29
3.03
0.831
0.73
0.399

0.2
2.72
0.881
0.8
0.463

0.2
20.19
1.711
0.93
3.256

0.22
2.27
0.729
0.64
0.359

MDL/2b
Minimum
Maximum
Mean
Median
SDd

0.19
3.03
0.817
0.73
0.415

0.1
2.72
0.856
0.8
0.491

0.1
20.19
1.705
0.93
3.259

0.12
2.27
0.7
0.64
0.386

MDL/√2c
Minimum
Maximum
Mean
Median
SDd

0.27
3.03
0.823
0.73
0.408

0.14
2.72
0.866
0.8
0.478

0.14
20.19
1.707
0.93
3.258

0.17
2.27
0.712
0.64
0.373

a

Values below the MDL were assigned the value of the MDL.
Values below the MDL were assigned the value of the MDL/2.
c
Values below the MDL were assigned the value of the MDL/√2
d
Standard Deviation
b
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Table 2: Summary Statistics for airborne benzene samples collected between
January 2003 and December 2006 for all Dade County sampling sites. All
concentrations are µg/m3.
Site
29

Site
32

Number of Samples
Number Below MDL

119
3

80
1

MDL
Minimum
Maximum
Mean
Median
SD

0.16
2.84
0.803
0.67
0.523

0.35
3.1
1.221
1.15
0.569

MDL/2
Minimum
Maximum
Mean
Median
SD

0.16
2.84
0.796
0.67
0.528

0.19
3.1
1.219
1.15
0.573

MDL/√2
Minimum
Maximum
Mean
Median
SD

0.16
2.84
0.799
0.67
0.525

0.28
3.1
1.22
1.15
0.571

a

Values below the MDL were assigned the value of the MDL.
Values below the MDL were assigned the value of the MDL/2.
c
Values below the MDL were assigned the value of the MDL/√2
d
Standard Deviation
b

27

Table 3: Summary Statistics for airborne benzene samples collected between
January 2003 and December 2006 for all Duval County sampling sites. All
concentrations are µg/m3.

Number of
Samples
Number
Below
MDL
Minimum
Maximum
Mean
Median
SDa

Site
32

Site
77

Site
80

Site
84

Site
100

96

54

48

89

48

0

0

0

0

0

1.41
24.79
6.09
4.52
4.34

1.09
24.09
4.28
3.37
3.47

1.41
34.50
6.18
4.70
5.33

1.05
28.62
7.68
6.87
4.79

0.05
14.95
3.62
3.42
2.59

Site
103

Site
104

Site
105

Site
101
Number
of
Samples
Number
Below
MDL
Minimum
Maximum
Mean
Median
SDa
a

Site
102

240

504

210

430

25

0

0

0

0

0

0.54
116.10
8.23
5.20
10.48

0.38
134.40
9.01
5.51
12.59

0.32
46.67
5.53
4.28
4.82

0.45
23.96
3.93
2.72
3.52

4.06
13.13
7.76
7.25
2.55

Standard Deviation
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Table 4: Summary Statistics for airborne benzene samples collected between
January 2003 and December 2006 for all Hillsborough County sampling sites.
All concentrations are µg/m3.

a

Site
1065

Site
1075

Site
3002

Number of Samples
Number Below MDL

218
0

57
0

177
0

Minimum
Maximum
Mean
Median
SDa

0.19
2.3
0.654
0.58
0.298

0.38
2.59
0.886
0.77
0.452

0.16
1.53
0.551
0.48
0.263

Standard Deviation
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Table 5: Summary Statistics for airborne benzene samples collected between
January 2003 and December 2006 for all Orange County sampling sites. All
concentrations are µg/m3.
Site
2002
Number of Samples
Number Below MDL

122
3

MDLa
Minimum
Maximum
Mean
Median
SDd

0.35
1.69
0.734
0.67
0.291

MDL/2b
Minimum
Maximum
Mean
Median
SDd

0.32
1.69
0.726
0.67
0.298

MDL/√2c
Minimum
Maximum
Mean
Median
SDd

0.35
1.69
0.728
0.67
0.296

a

Values below the MDL were assigned the value of the MDL.
Values below the MDL were assigned the value of the MDL/2.
c
Values below the MDL were assigned the value of the MDL/√2
d
Standard Deviation
b
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Table 6: Summary Statistics for airborne benzene samples collected between
January 2003 and December 2006 for all Pinellas County sampling sites. All
concentrations are µg/m3.

a

Site
4

Site
18

Site
26

Number of Samples
Number Below MDL

59
0

240
0

147
0

Minimum
Maximum
Mean
Median
SDa

0.35
1.92
0.853
0.73
0.378

0.16
2.78
0.826
0.73
0.444

0.26
4.66
1.039
0.93
0.629

Standard Deviation

3.2 Comparative Statistics for the Different Methods of Assigning Values to
Measurements Below the MDL
As previously stated, the method used by the USEPA to assign values to
measurements under the MDL is to divide the MDL by 2. Other, more conservative
methods, are often used to assign these values including assigning the value of MDL
or assigning the value of the MDL divided by the square root of 2. In order to
determine if the differences in value assignment methodologies have a statistically
significant impact on the derivation of the mean (and consequently the UCL-AM of
the mean), a two-tailed, paired t-test was conducted to compare the data that resulted
from using the USEPA methodology (MDL/2) with the data that resulted from using
both the actual MDL and the MDL/√2. A statistically significant difference was
considered to be evident at a p-value less than 0.05. These results are summarized for
each site that contained values below the MDL, by county, in Tables 7 – 12.
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Table 7: The results of paired t-tests for each site in Broward County. A p-value
<0.05 indicates a statistically significant difference in mean concentration values
due to assigning values to measurements under the MDL with an alternative
methodology than that used by the USEPA (MDL/2).

Site 1002

MDL/√2
(p-value)
<0.001*

MDL
(p-value)
<0.001*

Site 2004

<0.001*

<0.001*

Site 3002

0.019*

0.018*

Site 5005

<0.001*

<0.001*

* Indicates a statistically significant difference in the derivation of means by
using the alternative methodology of assigning values below the MDL
compared to the method used by the USEPA (MDL/2).
Table 8: The results of paired t-tests for each site in Dade County. A p-value
<0.05 indicates a statistically significant difference in mean concentration values
due to assigning values to measurements under the MDL with an alternative
methodology than that used by the USEPA (MDL/2).

Site 29

MDL/√2
(p-value)
0.098

MDL
(p-value)
0.101

Site 32

0.320

0.320

Table 9: The results of paired t-tests for each site in Orange County. A p-value
<0.05 indicates a statistically significant difference in mean concentration values
due to assigning values to measurements under the MDL with an alternative
methodology than that used by the USEPA (MDL/2).

Site 2002

MDL/√2
(p-value)
0.0833

MDL
(p-value)
0.0833

The paired t-tests indicate that only the data collected in Broward County (sites 1002,
2004, 3002, 5005) are affected at a statistically significant level by using alternative
methods of assigning values to measurements under the MDL in the exposure
assessment. Consequently, only these sites will be presented with results calculated
from alternative methods of assigning values below the MDL in subsequent analyses.
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3.3 The Calculation of the 95% UCL-AMs using ProUCL
The 95% UCL-AMs for measured airborne benzene concentrations were calculated
using ProUCL software. These values, which are used in the subsequent risk
analysis, are summarized by site for each county in Tables 13 – 18. In Figures 2-7,
the 95% UCL-AMs are charted for a side by side comparison of the relative exposure
levels measured within each county. Figure 8 provides a side by side comparison of
all the 95% UCL-AMs for all monitoring sites in the State of Florida. As three
different methods were used to assign values to measurements below the Method
Detection Limit (MDL), 95% UCL-AMs were produced for each method for relevant
sites, and this is reflected in the following tables and figures.
Table 10: The 95% UCL-AMs for all measured airborne benzene concentrations
in Broward County between 2003 and 2006 by Site. All concentrations are
µg/m3.

Concentration
(MDL)a
Concentration
(MDL/√2)b
Concentration
(MDL/2)c

Site
1002
0.88

Site
2004
0.94

Site
3002
2.75

Site
5005
0.77

0.87

0.93

2.75

0.75

0.86

0.92

2.75

0.74

a

Values below the MDL were assigned the value of the MDL.
Values below the MDL were assigned the value of the MDL/√2.
c
Values below the MDL were assigned the value of the MDL/2.
b
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Figure 8: Summary of the 95% UCL-AMs for Broward County monitoring sites
for data collected from the years 2003 to 2006. Concentrations are expressed in
µg/m3.
3

2.5

2

Concentration
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1.5

Concentration
(MDL/sqrt 2)
Concentration
(MDL/2)

1

0.5

0
Broward 1002

Broward 2004

Broward 3002

Broward 5005

Table 11: The 95% UCL-AMs for all measured airborne benzene concentrations
in Dade County between 2003 and 2006 by Site. All concentrations are µg/m3.

Concentration
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Site 29

Site 32

1.01

1.33

Figure 9: Summary of the UCL-AMs for Dade County monitoring sites for data
collected from the years 2003 to 2006. Concentrations are expressed in µg/m3.
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Table 12: The 95% UCL-AMs for all measured airborne benzene concentrations
in Duval County between 2003 and 2006 by Site. All concentrations are µg/m3.

Concentration

Concentration

Site
32

Site
77

Site
80

Site
84

Site
100

6.72

4.95

7.13

8.57

4.32

Site
101

Site
102

Site
103

Site
104

Site
105

11.18

11.45

5.94

4.67

8.63
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Figure 10: Summary of the UCL-AMs for Duval County monitoring sites for
data collected from the years 2003 to 2006. Concentrations are expressed in
µg/m3.
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Table 13: The 95% UCL-AMs for all measured airborne benzene concentrations
in Hillsborough County between 2003 and 2006 by Site. All concentrations are
µg/m3.
Site 1065
Concentration

0.687
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Site
1075
0.982

Site
3002
0.584

Figure 11: Summary of the UCL-AMs for Hillsborough County monitoring sites
for data collected from the years 2003 to 2006. Concentrations are expressed in
µg/m3.
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Table 14: The 95% UCL-AMs for all measured airborne benzene concentrations
in Orange County between 2003 and 2006 by Site. All concentrations are µg/m3.
Site 2002
Concentration

0.771
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Figure 12: Summary of the UCL-AMs for the Orange County monitoring site
for data collected from the years 2003 to 2006. Concentrations are expressed in
µg/m3.
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Table 15: The 95% UCL-AMs for all measured airborne benzene concentrations
in Pinellas County between 2003 and 2006 by Site. All concentrations are µg/m3.

Concentration

38

Site 4

Site 18

Site 26

0.938

0.885

1.265

Figure 13: Summary of the UCL-AMs for Pinellas County monitoring sites for
data collected from the years 2003 to 2006. Concentrations are expressed in
µg/m3.
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Figure 14: Summary of the UCL-AMs for all sites for data collected from the
years 2003 to 2006. Concentrations are expressed in µg/m3.
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3.4 Risk Analysis
The risk analysis outcomes indicate that every monitoring site in the State of Florida
measured benzene concentrations (based on the UCL-AMs) that are consistent with a
lifetime (70 year) estimated cancer risk probability of greater than 1 x 10-6. Risk
values ranged from 4.56 x 10-6 to 8.93 x 10-5 using USEPA methodology for data
treatment and analysis. Risk estimates are summarized for each site, by county, in
tables 19 – 24. In Figures 9-14, risk estimates have been charted side by side, using
the FLDEP regulatory limit of 1 x 10-6 as the baseline for reference. Figure 15
provides a side by side comparison for the risk estimates of all counties in the State of
Florida, using the FLDEP regulatory limit of 1 x 10-6 as the baseline for reference.
Risk estimates were also calculated for the monitoring data using both alternative
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methods of assigning values to measurements below the MDL for relevant sites, and
this is reflected in the following tables and figures.
Table 16: Lifetime cancer risk probability estimates for Broward County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006.

Concentration
(MDL)a
Concentration
(MDL/√2)b
Concentration
(MDL/2)c

Site
1002

Site
2004

Site
3002

Site
5005

6.83E-06

7.31E-06

2.15E-05

6.00E-06

6.77E-06

7.23E-06

2.14E-05

5.87E-06

6.73E-06

7.19E-06

2.14E-05

5.80E-06

a

Values below the MDL were assigned the value of the MDL.
Values below the MDL were assigned the value of the MDL/√2.
c
Values below the MDL were assigned the value of the MDL/2.
b
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Figure 15: Lifetime cancer risk probability estimates for Broward County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006. The baseline for this chart is 1 x 10-6, the FLDEP’s acceptable
cancer risk.
2.60E-05

2.10E-05

1.60E-05
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1.00E-06
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Broward 2004
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Table 17: Lifetime cancer risk probability estimates for Dade County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006.

Concentration
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Site 29

Site 32

7.85E-06

1.04E-05

Figure 16: Lifetime cancer risk probability estimates for Dade County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006. The baseline for this chart is 1 x 10-6, the FLDEP’s acceptable
cancer risk.
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Table 18: Lifetime cancer risk probability estimates for Duval County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006.

Concentration

Site
32
5.24E05

Site
77
3.86E05

Site
80
5.56E05

Concentration

Site
101
8.72E05

Site
102
8.93E05

Site 103
4.63E05
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Site 84
6.69E05
Site 104
3.65E05

Site
100
3.37E05
Site
105
6.73E05

Figure 17: Lifetime cancer risk probability estimates for Duval County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006. The baseline for this chart is 1 x 10-6, the FLDEP’s acceptable
cancer risk.
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Table 19: Lifetime cancer risk probability estimates for Hillsborough County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006.

Concentration

Site 1065

Site 1075

Site 3002

5.36E-06

7.66E-06

4.56E-06
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Figure 18: Lifetime cancer risk probability estimates for Hillsborough County,
by monitoring site, based on the measured concentrations of benzene from the
years 2003 to 2006. The baseline for this chart is 1 x 10-6, the FLDEP’s
acceptable cancer risk.
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Table 20: Lifetime cancer risk probability estimates for Orange County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006.
Site 2002
Concentration

6.01E-06
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Figure 19: Lifetime cancer risk probability estimates for Orange County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006. The baseline for this chart is 1 x 10-6, the FLDEP’s acceptable
cancer risk.
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Table 21: Lifetime cancer risk probability estimates for Pinellas County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006.

Concentration

Site 4

Site 18

Site 26

7.32E-06

6.90E-06

9.87E-06
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Figure 20: Lifetime cancer risk probability estimates for Pinellas County, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006. The baseline for this chart is 1 x 10-6, the FLDEP’s acceptable
cancer risk.
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Pinellas 26

Figure 21: Lifetime cancer risk probability estimates for all counties, by
monitoring site, based on the measured concentrations of benzene from the years
2003 to 2006. The baseline for this chart is 1 x 10-6, the FLDEP’s acceptable
cancer risk.
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3.5 Cumulative Lifetime Exposures in ppm-years
In order to compare the collected exposure data to epidemiological studies involving
occupational cumulative lifetime benzene exposures, the UCL-AM concentrations
must be converted from µg/m3 to ppm, and then extrapolated into 70 year cumulative
environmental lifetime exposures based on the ORD Workshop on Inhalation Risk
Assessment methodology previously described. Cumulative lifetime exposures to
benzene ranged from 0.04 ppm-years to 0.70 ppm-years. The extrapolated
cumulative lifetime exposures for all sites, by county, are summarized in Tables 25 –
30. Figures 15 – 21 charts the side by side comparison of lifetime cumulative
exposures for the monitoring sites within each county. Figure 22 charts the side by
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side comparison of lifetime cumulative exposures for all monitoring sites in the State
of Florida. Lifetime cumulative exposures were extrapolated for the monitoring data
using both alternative methods of assigning values to measurements below the MDL
for relevant sites, and this is reflected in the following tables.
Table 22: Extrapolated 70 year lifetime cumulative exposures for Broward
County by monitoring site. All values are ppm-years.

Cumulative
exposure (MDL)a
Cumulative
exposure (MDL/√2)b
Cumulative
exposure (MDL/2)c

Site
1002

Site
2004

Site
3002

Site
5005

0.05

0.06

0.17

0.05

0.05

0.06

0.17

0.05

0.05

0.06

0.17

0.05

a

Values below the MDL were assigned the value of the MDL.
Values below the MDL were assigned the value of the MDL/√2.
c
Values below the MDL were assigned the value of the MDL/2.
b
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Figure 22: Extrapolated 70 year lifetime cumulative exposures for Broward
County by monitoring site in ppm-years.
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Table 23: Extrapolated 70 year lifetime cumulative exposures for Dade County
by monitoring site. All values are ppm-years.

Cumulative exposure

50

Site 29

Site 32

0.06

0.08

Figure 23: Extrapolated 70 year lifetime cumulative exposures for Dade County
by monitoring site in ppm-years.
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Table 24: Extrapolated 70 year lifetime cumulative exposures for Duval County
by monitoring site. All values are ppm-years.

Cumulative
exposure

Cumulative
exposure

Site
32

Site
77

Site
80

Site
84

Site
100

0.41

0.30

0.44

0.53

0.26

Site
101

Site
102

Site
103

Site
104

Site
105

0.69

0.70

0.36

0.29

0.53
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Figure 24: Extrapolated 70 year lifetime cumulative exposures for Duval County
by monitoring site in ppm-years.
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Table 25: Extrapolated 70 year lifetime cumulative exposures for Hillsborough
County by monitoring site. All values are ppm-years.

Cumulative
exposure

Site 1065

Site 1075

Site 3002

0.04

0.06

0.04
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Figure 25: Extrapolated 70 year lifetime cumulative exposures for Hillsborough
County by monitoring site in ppm-years.
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Table 26: Extrapolated 70 year lifetime cumulative exposures for Orange
County by monitoring site. All values are ppm-years.
Site 2002
Cumulative exposure

0.05
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Figure 26: Extrapolated 70 year lifetime cumulative exposures for Orange
County by monitoring site in ppm-years.
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Table 27: Extrapolated 70 year lifetime cumulative exposures for Pinellas
County by monitoring site. All values are ppm-years.

Cumulative exposure

Site 4

Site 18

Site 26

0.06

0.05

0.08
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Figure 27: Extrapolated 70 year lifetime cumulative exposures for Pinellas
County by monitoring site in ppm-years.

1.00

0.90

0.80

0.70

0.60

0.50

0.40

0.30

0.20

0.10

0.00
Pinellas 4

Pinellas 18

55

Pinellas 26

Figure 28: Extrapolated 70 year lifetime cumulative exposures for all counties by
monitoring site in ppm-years.
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3.6 Comparative Risk Analysis with Occupational Cohorts
A review of published literature examining the relationship between discreet ranges
of occupational benzene exposure and leukemia is summarized in Table 31. For all
studies, the highest exposure category that did not result in a statistically significant
association between benzene and leukemia was considered the No Observable
Adverse Effect Level (NOAEL) for that study. For all studies, the lowest exposure
category that resulted in a statistically significant association with leukemia was
considered the Lowest Observable Adverse Effect Level (LOAEL). No studies were
discovered that established a relationship between benzene and leukemia outcomes
for cumulative exposures below 1 ppm-years.
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Table 28: The No Observable Adverse Effect Levels (NOAEL) and the Lowest
Observable Adverse Effect Levels (LOAEL) for all studies used in the
comparative risk analysis.
Study

Measure of
Association

NOAEL

LOAEL

Swaen et
al. 2005

SMR

N/Aa

Seniori et
al. 2003

SMR

Guenel et
al. 2002

OR

Rushton et
al. 1997

OR

Wong et al.
1995

SMR

Collins et
al. 2003

SMR

Paxton
1996

SMR

Glass et al.
2006

OR

Glass et al.
2003

OR

Hayes et
al. 1997

RR

401.5
ppmyears
100-199
ppmyears
>5.5 <16.8
ppmyears
>45
ppmyears
40-200
ppmyears
>6
ppmyears
>5-50
ppmyears
Not
Reporte
d
>1-2
ppmyears
<40
ppmyears

Rinsky et
al. 1987

SMR

Schnatter
et al. 1996

OR

40-200
ppmyears
20219.8
ppmyears
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Evidence for
association
between
leukemogenesis
and cumulative
exposures
under 1 ppmyears
NO

>200
ppmyears
>16.8
ppmyears

NO

NO

N/Aa
NO
200-400
ppmyears
N/Aa

NO
NO

>50-500
NO
>8 ppmyears
>2-4
ppmyears
40-99
ppmyears

200-400
ppmyears
N/Aa

NO
NO

NO

NO

NO

Wong and
Gerhard
1995

SMR

40-200
ppmyears

200-400
ppmyears

NO

SMR = Standardized Mortality Ratio, OR = Odds Ration, RR = Risk Ratio
a

N/A indicates no association between cumulative lifetime benzene exposure and
leukemia was found in this study.
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Chapter 4.0: Discussion
4.1 USEPA Risk Assessment for Benzene
Using the USEPA Risk Assessment for Carcinogens methodology, the 70 year
lifetime risk of developing cancer from the exposure levels measured in this study
exceed the Florida DEP’s acceptable risk of 1 x 10-6 for all sites. In order to
determine what these results mean in terms of actual cancer outcomes that may result
from this exposure, it is necessary to examine the nature of regulatory risk assessment
and its limitations. Further, a comparison between historical and contemporary
epidemiological studies must be conducted to determine if the risks suggested by the
risk analysis using the USEPA Risk Assessment for Carcinogens methodology are
consistent with empirical evidence.

The basis for the model used to perform risk analysis for inhalational exposure to
benzene used by both the USEPA and FLDEP is published by the USEPA Integrated
Risk Information System (IRIS) (48). The risk model currently employed produces
risk probabilities specifically for the leukemia “tumor type”, based primarily on data
gathered from the Pliofilm Rubber Factory cohort in a study of workers
occupationally exposed to benzene, originally described by Infante et al. 1977 (10).
The data from this cohort is considered the be the highest quality amongst all current
studies examining the relationship between benzene exposure and leukemia as it has a
sufficient sample size to provide adequate statistical power, the least amount of
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uncontrolled ancillary exposures that may result in confounding, and the most
accurate exposure assessment compared to other occupational cohorts. This is not to
say, however, that the exposure assessment conducted in this cohort is absolutely
precise, in that the direct measurements of exposure do not describe the entirety of all
working lifetime exposures. Several exposure matrices have been proposed, based on
job classification, time spent on the job, and employment duration, combined with
direct exposure measurements to estimate the cumulative exposures of the Pliofilm
workers. USEPA IRIS identifies the exposure matrices proposed by Crump and
Allen 1984 and Paustenbach et al. 1993 to be the most compelling estimates of
cumulative exposure, and present both resulting models in their risk analysis
methodology (48, 113-114). As the model resulting from the Paustenbach et al. 1993
is the more conservative exposure matrix (which results in a risk model that produces
higher risk values than the model based on the Crump and Allen 1984 exposure
matrix), it is the model commonly employed by regulatory agencies, including the
FLDEP (113-114). The resulting IUR of 7.8 x 10-6 has been used to calculate risk
probabilities in the current research (48).

The second mitigating factor in the estimation of risk is the use of the linearized
multistage model to extrapolate risk values for exposures below that of which
exposure data actually exists. In the USEPA Guidelines for Carcinogen Risk
Assessment, the following qualification is indicated for risk probabilities produced
using the linearized multistage model:
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“It should be emphasized that the linearized multistage procedure leads to a
plausible upper limit to the risk that is consistent with some proposed
mechanisms of carcinogenesis. Such an estimate, however, does not
necessarily give a realistic prediction of the risk. The true value of the risk is
unknown, and may be as low as zero.” (110)
In the current dissertation, the above qualification is pointedly relevant to the
interpretation of the outcomes associated with the risk analysis of ambient airborne
benzene levels measured throughout the State of Florida. As we compare the risk
values produced in this research with actual exposure/outcome data present in the
scientific literature, it will become apparent that the true value of risk associated with
these measured exposure levels, is in fact, almost certainly zero.

4.2 Comparative Analysis
Rinsky et al. 1981, 1987 produced one of the first epidemiological studies describing
discrete categories of cumulative exposures to benzene and associated cancer
outcomes that had both a sufficient sample size to produce statistically significant
results and a limited amount of confounding chemical exposures (45, 115). As
indicated in Table 31, the NOAEL found in that research fell in the category of 40200 ppm-years of exposure. As a result of the risk model proposed by Rinsky et al.
1981, 1987 the data from this cohort has been scrutinized by several other researchers
including Crump and Allen 1984, Crump 1994, Paustenbach et al. 1993, and Wong
1995 with the intent of evaluating both the exposure matrix used by Rinsky et al.
1981, 1987 as well as the methodology used to develop a risk model (45, 113, 115117). While all authors who evaluated the Rinsky et al. 1981, 1987 exposure
estimates deemed them to underestimate the actual exposures experienced by the
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cohort, when evaluating the association between the same discreet categories used by
Rinsky et al. 1981, 1987, they produced similar results, in that no statistically
significant association was found between cumulative exposures ranging between 40200 ppm-years (or below) and leukemogenesis (45, 113, 115-117).

Several authors who have evaluated this cohort have been quite specific in noting the
evidence to support the supposition that benzene is a threshold carcinogen (though the
actual threshold is still debated). Paxton 1996 used the exposure estimates of Rinsky
et al. 1987, Crump 1994, and Paustenbach et al. 1993 to compare the association of
benzene cumulative exposures to leukemias using different exposure categories for
comparison than previous studies (45, 113, 116, 118). With any exposure matrix
used in previous studies, she found no association between benzene and leukemia at
cumulative exposures below 50 ppm-years, indicating: “The newly gathered
information continues to be consistent with a threshold model for leukemogenesis by
benzene” (118).

Wong 1995 used the data from this cohort to analyze the association between
leukemia (specifically AML), multiple myeloma, and cumulative exposure to
benzene (117). The results indicated no association exists for any cumulative
exposure and multiple myeloma, while the association between cumulative benzene
exposures and AML were confined to exposures exceeding 200 ppm-years (117).
Wong 1995 indicates that the concept of specificity has largely been ignored in the
causal analysis for this exposure/disease relationship, noting:
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“Three decades ago, Hill set forth criteria for assessment of causation. The
same criteria were used in evaluating cancer risks related to tobacco in the
Surgeon General's report on smoking, and by the International Agency for
Research on Cancer in evaluation of carcinogenicity. Specificity is one of the
major criteria for causation analysis. The analysis specific to AML presented
in this report shows the importance of taking specificity into consideration.
Previous analyses based on all leukaemia cell types combined have incorrectly
set the estimated threshold too low but underestimated risk above the
threshold. The estimated threshold specific to AML was found to be at least
200 ppm-years based on one set of exposure estimates; and much higher, had
other exposure estimates (most likely more accurate) been used” (117).
Another large benzene cohort exists, consisting of Chinese industrial workers, which
is currently under study (47). While this cohort is larger than the pliofilm cohort,
significant criticisms have prevented the research from being considered in the
creation of regulatory levels, as is indicated by the USEPA IRIS:
“Although the ongoing Chinese cohort studies (Dosemeci et al., 1994; Hayes
et al., 1996, 1997; Yin et al., 1987, 1989, 1994, 1996) provide a large data set
and perhaps may provide information in the future to better characterize risk
of cancer at low dose exposure, their use in the derivation of risk estimates
remains problematic at present…Limitations of this study include possible
concurrent exposures to many different chemicals found in the factories where
the benzene exposure occurred. There is a lack of reliable exposure
information in the early days of the observation period, when only 3% of the
exposure estimates were based on actual measurements…The limitations of
these studies, except for Rinsky et al. (1981, 1987), preclude their use in
quantitative risk estimation” (48).
Despite these issues, research based on this cohort does provide some valuable
evidence towards the discovery of a threshold level of cumulative lifetime benzene
exposure, below which there is no association with leukemogenesis. Hayes et al.
1997 provides a comprehensive analysis of the Chinese worker cohort, which
produced no statistically significant associations between <40 ppm-years of
cumulative benzene exposure and leukemia, non-Hodgkin’s lymphoma, acute
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lymphocytic leukemia, acute lymphocytic leukemia and myelodysplastic syndromes,
or other leukemias (47).

Hayes et al. 1997 did find a statistically significant association when they compared
all hemotologic neoplasms to their lowest cumulative exposure group (<40 ppmyears). In light of the circumstances surrounding that finding, it is difficult to regard
it as meaningful, in terms of assigning a causal association between low levels of
cumulative benzene exposure and hemotologic neoplasms. As was noted by USEPA
IRIS, and is confirmed by Hayes et al. 1997, the workers in this cohort were exposed
to a variety of industrial manufacturing solvents, which could not be controlled for in
analysis (47-48). As well, to reiterate the proposition made by Wong 1995,
specificity is often overlooked in the assessment of causal associations between
exposures and diseases; and in this case, we have an association which is neither
specific in terms of exposure, nor in terms of disease (119). As well, when the dose
response for increasing levels of exposure is examined for this disease category, a
dose response is notably absent. The Risk Ratios for each in increasing exposure
category were reported as: 2.2 (<40 ppm-years), 2.9 (40 – 99 ppm-years), and 2.7
(>100 ppm-years), displaying no clear increase of risk with relatively large increases
of cumulative exposure (47). The lack of dose response found in this study is also
evident in the outcomes for leukemia. The Risk Ratios reported for leukemia were
non-significant at (<40 ppm-years), 3.1 at (40 – 99 ppm-years), and 2.7 at (>100
ppm-years) (47). It is not clear from these results that there is an increased risk of
leukemia from 100 ppm-years of exposure compared to 40 ppm-years of exposure.
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With a study cohort of 74,828 exposed workers, it is unlikely that sample size was
limiting factor of the analysis; more likely, this lack of a robust dose-response is due
to the fact that the cohort is made up of workers from a diverse field of industries
which makes an accurate exposure assessment difficult (especially when the same
methodology is used to assign exposures to workers in different environments), as
well as making it nearly impossible to control for confounding chemical exposures. It
is principally these reasons that the USEPA rejects the Hayes et al. 1997 data as being
acceptable for developing quantitative risk analysis. In light of these shortcomings, it
is fair to say that the pliofilm cohort provides clearer evidence of a threshold for
leukemogenesis due to cumulative benzene exposure (somewhere between 50 – 200
ppm-years), whereas the Hayes et al. 1997 data suggests a threshold somewhere
below 40 ppm-years (47-48). It is certain that the Hayes et al. 1997 data do not
provide any evidence that there may be any risk of leukemogenesis at exposures
below 1 ppm-years, and as well, do not provide strong evidence to contradict the
threshold of >50 ppm-years found in the pliofilm cohort (45-48, 113, 115-117).

Wong and Gerhard 1995 conducted another cell type specific meta-analysis of
leukemias associated with cumulative benzene exposures in a cohort of petroleum
workers from the United Kingdom and the United States (119). The results of this
analysis were directly comparable to the findings in numerous analyses in the
American pliofilm cohort. No statistically significant associations were found
between any leukemia type and cumulative benzene exposures below 200 ppm-years
(119). One of the major strengths of this study is the large sample size, including the
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evaluation of 208,741 exposed workers (119). It should be noted that the authors
indicate exposures may have been underestimated for some groups (especially those
in the highest exposure groups) because in addition to their less well controlled
working conditions, it is believed many workers were exposed more than 8 hours a
day for a 5 day work week, which was the exposure standard used in the exposure
assessment (119). This potential underestimation of exposure leads Wong and
Gerhard 1995 to believe that risk at 200 ppm-years of cumulative exposure may
actually be overestimated, and that the threshold for leukemogenesis may actually be
much higher (119).

Rushton and Romaniuk 1997 performed a smaller case control study (91 exposed
cases), also using petroleum workers from the United Kingdom (120). Workers in
this study had significantly lower exposures than found in previously discussed
studies, the highest exposure group evaluated being > 45 ppm-years of exposure
(120). The authors of this study were not able to find any association between
cumulative benzene exposure and leukemia, supporting the previous findings that a
threshold exists for cumulative benzene exposures exists for leukemogenesis, and that
the threshold is in great excess of environmental levels (120).

Guenel et al. 2002 performed a small case control study (72 exposed cases) in Gas
and Electric Utility Workers (121). These workers were typically classified has
having much lower cumulative exposures than other occupational groups previously
examined, with the highest exposure group being >16.8 ppm-years (121). The initial
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findings of this study indicate a statistically significant association between all
leukemias and cumulative benzene exposures of >16.8 ppm-years, however, further
evaluation of this study diminishes the importance of this finding (121). The
exposure assessment performed by Guenel et al. 2002 suffers from the common
affliction found in the majority of epidemiological studies examining the relationship
between benzene and leukemia: the potential underestimation of exposure levels
(121). As is often criticized by other researchers examining this issue, low level
exposures are not found to be specifically associated with any specific cell type, and
this was apparent in Guenel et al. 2002 who failed to demonstrate any statistically
significant association between cumulative benzene exposures and any specific
leukemia, including AML, acute lymphoid leukemia, all chronic leukemias, chronic
myeloid leukemia, and chronic lymphoid leukemia (121). Finally, when the odds
ratio for all leukemias and cumulative exposure group of greater than 16.8 years is
adjusted for confounding exposures (asbestos, chlorinated solvents, and coal tars), the
estimated association loses statistical significance, and thereby also loses any utility
as evidence for determining that low level cumulative benzene exposure is a causative
agent for leukemia (121).

Glass et al. 2003, 2006 also attempts to find an association between low cumulative
benzene exposure levels and various hemotopoietic cancers in a small case control
study (79 total cases, 33 cases of leukemia) examining Australian petroleum workers
(122-123). The authors report a statistically significant association between
leukemias and cumulative benzene exposure at >2-4 ppm-years [OR = 6.1 (1.4–
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26.0)], a non-significant association at >4-8 ppm-years [OR = 2.4 (0.4–13.6)], a
significant association at >8-16 ppm-years [OR = 5.9 (1.3–27.0)], and a greatly
elevated significant association at >16 ppm-years [OR = 98.2 (8.8–1090)] (122-123).
The first notable weakness of these results is the inconsistency of dose response
throughout the exposure categories (122-123). As almost all of the cases selected for
this analysis fall into a narrow range of low level exposures, if a true association
existed at these exposure levels, one would expect a clear dose-response to be
apparent when the cumulative exposure essentially doubles by every increasing
exposure category (122-123). As the results are presented, it is clear this is not the
case. In fact, due the extreme variance in the data, it is difficult to determine if a
dose-response is occurring between any levels of exposure, even the between the two
highest categories (122-123). While superficially, it may seem that a quantifiable
increase is occurring between the >8-16 ppm-years exposure level (OR = 5.9) and the
highest exposure level of >16 ppm-years (OR = 98.2), an examination of the
extensive confidence intervals associated with those OR point estimates indicates two
important characteristics of these data (122-123). Firstly, the point estimates for these
are relatively meaningless (especially for the highest exposure group), as there is
equal probability that the point estimate indicated by the regression model could
actually be any value within the 95% confidence interval (122-123). Therefore, the
actual strength of association presented in these results is unknown. Secondly, the
width of the confidence intervals show a significant amount of overlap between the
outcomes of the last two exposure groups, indicating that while the point estimates
would seemingly suggest a tremendous dose response from 5.9 to 98.2, it is actually
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impossible to ascertain whether or not such a large dose-response is occurring in this
study, or if any dose-response relationship exists at all at these levels of exposure
(122-123).

Perhaps the greatest criticism that could be made of this research is the exposure
assessment methodology. The authors disclose that they used essentially the same
methodology of assigning exposure to workers exposed after 1975 as workers
exposed before 1975 as a result of “uncertainty about exposures before 1975” (123).
By doing this, the authors have undoubtedly underestimated exposures in this study
by not accounting for changes in workplace practices and regulations that would have
led to significantly different exposure levels in the workplace. In some cases, they
have attributed more current exposure levels to workers whose principle exposures
occurred before 1975, which for some workers, represented of 30 or more years of
their exposure duration (122-123)!

It is obvious that the exposure assessment of the cohort used in Glass et al. 2003,
2006 has not been scrutinized to the degree that the more highly regarded exposure
assessment in the pliofilm cohort has. The research by Glass et al. 2003, 2006
essentially represents 33 cases of leukemia that produce widely variant measures of
association, no definitive dose response, and an analysis based on an exposure
assessment that almost certainly underestimated worker exposure to a significant
degree (122-123). In addition, these results are a unique finding, which have failed to
be replicated by other researchers. Without addressing these key factors, this research
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cannot provide adequate evidence to invalidate the threshold exposure level of > 50
ppm-years as found in the pliofilm cohort, and without question, the evidence
provides no support to the supposition that there may be a risk of leukemogenesis
when exposed to 1 ppm-years or less of airborne benzene.

There have been several other recent epidemiological studies evaluating the
relationship between benzene exposed workers and leukemogenesis, including
Collins et al. 2003, who specifically evaluated low level cumulative exposures in their
analysis (124). Collins et al. 2003 examined a cohort of 4417 chemical plant workers
with cumulative exposure categories of: unexposed, less than 1 ppm-years, 1-6 ppmyears, and >6 ppm-years (124). No association between cumulative benzene
exposure and leukemia could be established for any exposure group, the authors
noting, “The dose rate of benzene and a threshold for exposure response may be
important factors for evaluating lymphohaematopoietic risk (124).”

Seniori-Constantini et al. 2003 evaluated benzene exposure and leukemia deaths
amongst 1687 exposed shoe factory workers (125). To make their results comparable
to the findings of other larger cohorts, specifically the Pliofilm cohort (Rinsky et al.
1987, Paustenbach et al. 1993, Crump 1994, Paxton 1996), similar exposure
categories were evaluated; that of <40 ppm-years, 40-99 ppm-years, 100-199 ppmyears, and >200 ppm-years (45, 113, 116, 118, 125). Seniori-Constantini et al. 2003
failed to find an association between cumulative benzene exposure and leukemia at
any exposure level except for those exposed to more than 200 ppm-years. These
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results are in direct agreement with those found in the pliofilm cohort, clearly
supporting historical evidence of a threshold for benzene exposure and
leukemogenesis (125).

Swaen et al. 2005 evaluated 311 Caprolactam workers in the Netherlands with
benzene exposure (126). The authors of this study chose to divide their exposure
categories into the mean cumulative exposures for each tertile (126). The mean
cumulative exposures for each tertile were 3.4 ppm-years, 68.8 ppm-years, and 401.5
ppm-years (126). The results of this analysis did not find an association between
benzene exposure and excess leukemia (126). An obvious weakness of this study is
the small sample size of the cohort, though using the tertile divisions created exposure
categories that were nearly equivalent in size from the first to the third quartile (n =
94, 88, and 93 respectively) (126). While this study admittedly does not share the
degree of statistical power found in previous studies, it certainly adds to the weight of
evidence supporting a threshold level of benzene exposure below which there is no
risk of leukemogenesis, and as well, this study contributes evidence to the supposition
that this threshold exists at or above 50 ppm-years (126).

Similarly, Schnatter et al. 1996 performed a case control study with a small group of
Canadian petroleum workers (14 cases) to evaluate the relationship of their benzene
exposure and leukemia (127). The cumulative benzene exposures ranged from 0 to
219.8 ppm-years (127). The authors attempted to assess various exposure categories
to create the largest exposure groups possible, despite their small sample size, with
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the highest exposed category being those with 20 to 219.8 ppm-years of exposure
(127). The authors of this study failed to find an association between any exposure
category and leukemia (127). Obviously, the small sample size would hinder the
ability to find a significant association between cumulative benzene exposure and
leukemia if it existed, but it is important to note that the sample size did provide
enough statistical power to find statistically significant associations between smoking
history, and a family history of cancer with leukemia (127). So, while this study does
have significant limitations, it is consistent with the compilation of studies that
examine cumulative lifetime benzene exposures (127).

The lifetime cumulative benzene exposures calculated in the current risk
characterization, extrapolated from the measured exposures from each monitoring
site, ranged from 0.04 ppm-years to 0.70 ppm-years. Based on the weight of
scientific evidence presented, which indicates that the threshold for leukemogenesis
exists at or above 50 ppm-years of cumulative lifetime benzene exposure, it can be
seen that the measured exposures in this study are approximately 50 to 1000 times
lower than cumulative exposures that are capable of producing leukemogenesis.
Without exception, no research to date has found evidence of an association between
leukemogenesis and the lifetime cumulative benzene exposures measured in this
study, of which all fall below 1 ppm-years.

Another finding in the scientific literature that is of direct interest to the current risk
characterization is that of the relationship between peak exposure concentrations in
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addition to cumulative lifetime exposure as a driver for leukemogenesis. Several
authors have noted that in addition to a significant cumulative exposure ranging from
50 to greater than 200 ppm-years, an extended period of peak exposure must also be
experienced in order for leukemogenesis to occur. Schnatter et al. 1996b found that
leukemia cases were associated with extended exposures of 20 – 25 ppm using
minimal exposure estimates, but potentially as high as 50 – 60 ppm using higher
exposure estimates in addition to significant cumulative exposure (127). Collins et al.
2003 noted that there was no indication of risk from the low levels of cumulative
exposure experienced by their cohort, but that increased risk could be attributed to
those who were exposed to 100 ppm for 40 days or more (124). The maximum
benzene level recorded in the State of Florida from 2003 to 2006, was 134.4 µg/m3
(0.042 ppm) and can be found in Table 3 for monitoring site 102 in Duval County.
When comparing these peak levels of exposure to those found in occupational
settings that may be required to initiate, or otherwise drive leukemogenesis, it is clear
that this potential mechanism for leukemogenesis does not come into play in terms of
the ambient environmental exposures reported in this research.

4.3 Statistical Considerations for the Method Detection Limit
As is indicated in Table 7, the alternative methods of assigning values below the
MDL did produce statistically different mean values for all monitoring sites in
Broward County. This indicates that a considerable number of values within those
data sets were reported as being under the method detection limit. The
meaningfulness of this finding can be interpreted by examining the results of the risk
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analysis and cumulative exposure analysis between these three data treatment
methods.

In Table 19, the risk values produced for each monitoring site in Broward County are
shown for all three methods of assigning values. The results for all sites, and all
methods, are homogenous in the following: all methods produce risk values that are
in excess of the 1 x 10-6 acceptable risk as indicated by the FLDEP. In fact, the
differences in probabilities fall on the order of minutia, the largest difference
occurring in the data from Site 5005 where the largest estimate of risk (assigning the
MDL) equals 6.00 x 10-6 and the lowest estimate of risk (assigning the MDL/2)
equals 5.80 x 10-6. This represents a 0.2 millionth increase in risk using the more
conservative method. In Table 25, the cumulative exposure values for all monitoring
sites in Broward Country are shown. As values have been rounded to the nearest
hundredth, no discernable difference is seen in the calculation of cumulative
exposure, regardless as to which method has been used.

In Table 8 and Table 10, the t-test comparisons are shown for Dade County and
Orange County, respectively. These results indicate that no statistically significant
difference on the outcomes was produced regardless of what method of assigning
values was used.
Tables 9, 10, and 12 show the t-test comparisons for Duval, Hillsborough, and
Pinellas Counties, respectively. As no values below the method detection limit were
reported for any monitoring sites in these counties, no statistical comparisons could
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be made for methodological differences, and obviously, it can be said that values
under the method detection limit had no influence in the risk analysis or cumulative
exposure analysis for these any of these county’s monitoring sites.
4.4 Study Limitations
A primary criticism of the current study may be the generalizability of the exposure
assessment. Unfortunately, air toxics monitoring at this time is very limited, to the
extent that few counties have active monitoring sites, and those that do, have very few
monitors. While the ability to perform exposure and risk calculations based on actual
sampling data has the advantage of using a validated methodology to enumerate
airborne benezene concentrations, emissions modeling has the advantage of
estimating exposures in locations that are not monitored. So with the data used in this
dissertation, it is not possible assert that there are no locations within the State of
Florida that are polluted with higher concentrations of benzene than are represented in
this study. However, an examination of the monitor locations and the proximity of
potential emission sources would indicate that the monitoring data used in this study
represents an accurate cross section of typical ambient exposures in populated areas,
with monitor locations ranging from more rural locations to more industrial locations,
several within two miles of some of the largest benzene emission sources in their
respective county. Indeed, when examining the monitor location maps (Figures 2-7)
we find that the highest measured ambient levels are found in Duval County. Several
of the Duval County monitors are located in dense Commercial/Industrial areas, and
are consequently subjected to the benzene emissions from these point source
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polluters. As well, most monitors are located near major roadways and highways,
whose fugitive emissions from automobiles contribute significantly to the ambient
levels of benzene.

Likewise, when we examine the lowest monitored levels, they are found in rural
areas, such as Site 3002 in Hillsborough County (Figure 4) and in residential areas
such as Site 5005 in Broward County, which are further removed from both fugitive
and point source benzene emissions. While it is fair to say the exposure assessment
performed in this study is not comprehensive, the results should provide a reasonable
description of the exposure intensity for a large proportion of the general public.

It has been noted that Duval County uses a different sampling methodology than all
other Florida Counties. At the same time, the results indicate Duval County
measured the highest maximum levels, the highest mean levels, and maintained the
largest variance in measurements of any county. Several Duval monitoring sites
measured peak levels, mean levels, and standard deviations over an order of
magnitude higher than sites in other counties (Table 3). A potential cause of these
differences would be the shorter sample times (3 and 4 hour samples) sometimes used
by Duval county. If samples are taken during peak emissions times for a 3 hour
period, it would potentially overestimate the mean concentrations at that site. This is
not clear evidence that the Duval County measurements are erroneous, and the higher
mean levels may be explained by greater industrial and interstate highway density
within that county; however the extreme variance found within the Duval County
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may be indicative of poor sampling methodology that results in an over estimation of
exposure. Even if this is the case, however, it does not affect the fundamental
conclusions of this research.

All research is subject to limitations, the current research being no exception.
However, the limiting factors in this research are not sufficient to warrant a rejection
of the primary conclusions drawn from the study results.
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Chapter 5.0: Conclusions
This investigation used historic airborne monitoring data from six counties in the
State of Florida to characterize the cancer risk from airborne benzene concentrations
used current Federal and State regulatory risk characterization methodologies, and a
comparative risk analysis based on occupational epidemiologic evidence. Airborne
benzene concentrations were collected from 23 air toxics monitoring stations in
Broward, Duval, Orange, Miami-Dade, Hillsborough, and Pinellas counties during
the years 2003-2006. Using the risk calculation methodology found in the EPA and
the Florida Department of Environmental Protection (FLDEP) guidelines, the
resulting cancer risk estimates ranged from 4.37 x 10-6 to 8.56 x 10-5, which exceed
the FLDEP’s acceptable cancer risk level of 1 x 10-6 for all monitoring sites. The
cumulative lifetime exposures were calculated in ppm-years, by site, and ranged from
0.036 - 0.702 ppm-years. A comparative analysis with available epidemiological
literature revealed that the association between benzene exposure and cancer risk is
related to cumulative exposure clearly in excess of 1 ppm-years, with a threshold of
carcinogenesis potentially in excess of 50 ppm-years. The results of this investigation
indicate that it is unreasonable to expect additional cancer cases in Florida residents
due to measured ambient airborne benzene levels, despite the fact that all regulatory
risk calculations exceed acceptable cancer risk levels in the State of Florida.
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The implications of these results are highly relevant to contemporary practices of risk
assessment and risk communication in terms of the economic consequences as well as
the impact on public perception of risk from regulatory risk assessments. The FLDEP
utilizes the same regulatory risk assessment methods found in this research to
determine remediation levels for soil contaminated with benzene. The unit risk
values used to analyze risk from soil intake or water intake resulting from
contaminated soil is derived from the same cancer slope factor used for determining
inhalation risk, a product of the linearized multi-stage model. Consequently, risk
values for those two media have the same validity (or rather lack of validity) as those
calculated for airborne exposures.

Gasoline fuel stations are common targets of soil remediation in Florida due to
benzene contamination resulting in risk values above 1 x 10-6 for either soil or water
intake. It has been reported that the typical gas station site costs $97,000 for soil
treatment, with a range in costs from $22,000 to $260,000 (129). This money is spent
under the assumption that by remediating the contaminated soil, a significant
reduction to public health risk will be achieved. The results of the current research
indicate that this is clearly not the case in any instance in which the soil or water
benzene concentration results in a risk 1 to 2 magnitudes of order over the allowable
limit using the regulatory risk analysis methodology. Under these circumstances, not
only are economic resources essentially wasted, but over the course of 26 – 60
months (the typical remediation period) needless amounts of fuel is consumed, and
needless amounts of combustant pollution is produced during this process (129).
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Communicating health risk to the general populace is a significant responsibility held
by researchers and regulators alike. Is it a responsible act to communicate to the
public trust that, essentially, the air they breathe may be putting their health at risk?
By using the USEPA and FLDEP specified methods and the linearized multistage
model to “quantify” risk, we are essentially communicating to the public that not only
does every molecule of benzene in the air pose some calculable amount of risk to
their health, but further, that the amount of benzene present exceeds the amount of
risk we, as researchers and regulators charged with serving the public trust, deem
acceptable. Clearly, this is not a responsible means of presenting risk and the current
research illustrates the inherent fallacy in using the current regulatory method to
assess the health risk of low level carcinogen exposures in the State of Florida.
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APPENDIX A
Summary of Epidemiological Studies used for Comparative Analysis

Study

Rinsky et
al. 1987

Measure of
Association

SMR

NOAEL

40-200
ppmyears

92

LOAEL

200400
ppmyears

Comments on Utility
for Causal Inference

*High number of
actual exposure
measurements
(considered the
best exposure
assessment
among similar
studies); Specific
exposure\disease
outcomes;
Significant
measures of
association; Clear
dose-response;
Consistent results
compared to
similar studies.
Suitable evidence
for causal
inference.

Paxton
1996

Wong
and
Gerhard
1995

SMR

>5-50
ppmyears

>50500

SMR

40-200
ppmyears

200400
ppmyears

93

*Same cohort as
Rinsky et al. 1987
with updated
exposure
matrices; more
refined exposure
categories to
assess lower level
exposures;
Specific
exposure\disease
outcomes;
Significant
measures of
association; Clear
dose-response;
Consistent results
compared to
similar studies;
Most
conservative
measures of
association using
the best exposure
assessment; This
study is the basis
for the estimated
threshold of
benzene induced
leukemogenesis
being in excess of
50 ppm-years.
Suitable evidence
for causal
inference.
*High number of
actual exposure
measurements;
Specific
exposure\disease
outcomes (cell
specific analysis);
Significant
measures of
association; Clear

dose-response;
Consistent results
compared to
similar studies.
Suitable evidence
for causal
inference.

Seniori et
al. 2003

Wong et
al. 1995

SMR

100199
ppmyears

>200
ppmyears

SMR

40-200
ppmyears

200400
ppmyears

94

*High number of
actual exposure
measurements;
Specific
exposure\disease
outcomes;
Significant
measures of
association; Clear
dose-response;
Consistent results
compared to
similar studies.
Suitable evidence
for causal
inference.
*High number of
actual exposure
measurements;
Specific
exposure\disease
outcomes (cell
specific analysis);
Significant
measures of
association; Clear
dose-response;
Consistent results
compared to
similar studies.
Suitable evidence
for causal
inference.

Hayes et
al. 1997

Collins et
al. 2003

Schnatter
et al.
1996

RR

<40
ppmyears

40-99
ppmyears

SMR

>6
ppmyears

N/A

OR

20219.8
ppmyears

N/A

95

*Large sample
size; Various
incomparable
working
environments and
exposures applied
to all workers;
Exposure
assessment
somewhat
speculative;
Lacks specificity.
Less suitable for
causal inference.
*Large sample
size; Examines
low level
exposures; Less
actual measured
exposures in
exposure matrix;
Failed to find an
association
between benzene
exposure and
leukemogenesis.
Less suitable for
causal inference.
*Largely
speculative
exposure
assessment;
Smaller sample
size; Relatively
large statistical
variance;
Uncontrolled
confounders; Less
desirable casecontrol study
design; No
definitive dose
response; Failed
to find an
association

between benzene
exposure and
leukemogenesis.
Unsuitable for
causal inference.

Glass et
al. 2006

Glass et
al. 2003

OR

Not
Report
ed

>8
ppmyears

OR

>1-2
ppmyears

>2-4
ppmyears

96

*Largely
speculative
exposure
assessment;
Smaller sample
size; Relatively
large statistical
variance;
Uncontrolled
confounders; Less
desirable casecontrol study
design; No
definitive dose
response.
Unsuitable for
causal inference.
*Largely
speculative
exposure
assessment;
Smaller sample
size; Relatively
large statistical
variance;
Uncontrolled
confounders; Less
desirable casecontrol study
design; No
definitive dose
response.
Unsuitable for
causal inference.

Guenel et
al. 2002

Rushton
et al.
1997

OR

>5.5 <16.8
ppmyears

>16.8
ppmyears

OR

>45
ppmyears

N/A

97

*Largely
speculative
exposure
assessment;
Smaller sample
size; Relatively
large statistical
variance;
Uncontrolled
confounders; Less
desirable casecontrol study
design; No
definitive dose
response; Failed
to find a
statistically
significant
association
between benzene
exposure and
AML. Unsuitable
for causal
inference.
*Largely
speculative
exposure
assessment;
Smaller sample
size; Relatively
large statistical
variance;
Uncontrolled
confounders; Less
desirable casecontrol study
design; No
definitive dose
response; Failed
to find an
association
between benzene
exposure and
leukemogenesis.
Unsuitable for

causal inference.

Swaen et
al. 2005

SMR

401.5
ppmyears

98

N/A

*Largely
speculative
exposure
assessment;
Smaller sample
size; Relatively
large statistical
variance;
Uncontrolled
confounders; Less
desirable casecontrol study
design; No
definitive dose
response; Failed
to find an
association
between benzene
exposure and
leukemogenesis.
Unsuitable for
causal inference.
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